Leveraging these findings, our engineered CD38‐EVs‐DoxMNs may enhance MM treatment efficacy when combined with standard regimens, including proteasome inhibitors or immunomodulatory drugs. The gene discussed is CD38; the disease is Miyoshi myopathy.